News
FDA approves cabozantinib for previously treated HCC
Approval was based on improvement in overall survival versus placebo in the phase 3 CELESTIAL trial.
News
BMI changes in adolescence linked to later cancer risk
Adiposity changes during the peripubertal period may have more of an impact on ovarian cancer risk than adiposity changes during adulthood.
News
FDA approves Elzonris for blastic plasmacytoid dendritic cell neoplasm
This is the first approved therapy for BPDCN, an aggressive and rare disease of the bone marrow and blood that can affect multiple organs, and can...
News
FDA approves olaparib for maintenance treatment of BRCA-mutated advanced ovarian cancer
The FDA also approved a companion diagnostic, the BRACAnalysis CDx test, to identify patients with gBRCAm advanced epithelial ovarian, fallopian...
News
FDA approves Nplate for pediatric ITP
Approval is for pediatric patients who’ve had ITP for at least 6 months but had no good response to corticosteroids, immunoglobulins, or...
News
Atezolizumab combination regimen approved for advanced non-squamous NSCLC
The FDA approved checkpoint inhibitor atezolizumab for the treatment of metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor...
News
Similarity of CT-P6 and trastuzumab remain with longer follow-up
The efficacy and cardiac toxicity profile between trastuzumab biosimilar candidate CT-P6 and trastuzumab, as neoadjuvant and then adjuvant therapy...
News
SABCS 2018: Can CTCs determine treatment for advanced breast cancer?
Results of the phase 3 STIC CTC trial will address the clinical utility of circulating tumor cells in choosing treatment approaches.
News
SABCS 2018: PHARE, KATHERINE, and KATE2 in HER2+ breast cancer
Studies in HER2+ breast cancer to be presented at SABCS include a comparison of 6 vs. 12 months of trastuzumab, T-DM1 vs. trastuzumab following...
News
FDA approves larotrectinib for cancers with NTRK gene fusions
Larotrectinib is approved for patients with solid tumors that have progressed following treatment and harbor a NTRK gene fusion without a...
News
SABCS 2018: Further analysis on IMpassion130 for mTNBC
Investigators presented results of the phase 3 IMpassion130...
News
FDA approves lorlatinib as second line for ALK-positive advanced NSCLC
The approval was based on an overall response rate of 48% in patients previously treated with one or more ALK kinase inhibitors.
News
ESMO 2018: First look at immunotherapy as first-line treatment for HNSCC
Results of KEYNOTE-048, a study of pembrolizumab for first-line treatment of recurrent or metastatic HNSCC, will be presented at ESMO 2018.
News
Updated analysis from JAVELIN Renal 101 to be presented at ESMO 2018
The phase 3 trial compared immunotherapy in combination with a tyrosine kinase inhibitor to sunitinib montherapy as first-line therapy for...